Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm Pharmaceuticals reported positive results from the Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity, showing significant reduction in BMI with no new safety concerns.